Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 32M P/E - EPS this Y 48.30% Ern Qtrly Grth -
Income -28.05M Forward P/E -1.47 EPS next Y -35.50% 50D Avg Chg 17.00%
Sales 201k PEG -0.03 EPS past 5Y - 200D Avg Chg 31.00%
Dividend N/A Price/Book 0.93 EPS next 5Y 25.00% 52W High Chg -21.00%
Recommedations 2.00 Quick Ratio 1.14 Shares Outstanding 57.14M 52W Low Chg 128.00%
Insider Own 9.55% ROA -80.04% Shares Float 47.60M Beta -0.38
Inst Own 14.78% ROE -154.79% Shares Shorted/Prior 498.08K/569.96K Price 0.66
Gross Margin 71.14% Profit Margin - Avg. Volume 125,429 Target Price 3.50
Oper. Margin -7,388.00% Earnings Date Nov 13 Volume 105,092 Change 3.12%
About AIM ImmunoTech Inc.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

AIM ImmunoTech Inc. News
11/20/24 Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
11/19/24 AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
11/16/24 AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
11/15/24 AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/06/24 AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast
11/04/24 AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
10/09/24 AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
10/03/24 AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
09/30/24 AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
09/27/24 AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
09/19/24 AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
09/11/24 AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
08/20/24 AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
08/16/24 AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/13/24 AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
07/29/24 AIM ImmunoTech Announces Release of the Next CEO Corner Segment
07/24/24 AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
06/10/24 AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
06/03/24 AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
05/31/24 AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
AIM Chatroom

User Image Ampligenmillionaire Posted - 5 minutes from now

$AIM I have been very conflicted as to who vote for or even splitting my vote. I have decided to vote for Kellner group. Simple reason is Trump is president. Kellner was RNC chair and probably helped deliver Wisconsin.

User Image EatFreeLunches Posted - 5 hours ago

$AIM stock keeps getting cut in half every year. Could Kellner do a worse job if he tried?

User Image Parveenfae Posted - 7 hours ago

$AIM bullish on this 👍🏻

User Image Maxwell_Smart Posted - 7 hours ago

$AIM This is plausible.

User Image Jaortiz Posted - 8 hours ago

$AIM I have had many questions and many longs will agree and disagree . Everyone keeps pointing out the kellner group is shorting the stock? But they are also the ones who have a really large position . The naked shorting has been going on WAY before they have been involved in AIM. My big worry is if the shorts have it out for AIM wouldn’t that be on the current management team and a chance it would change with new leadership? I have really been thinking even a split board would be the most beneficial for longs. Whatever happens I just hope we can see the light and get ampligen on the market. I wish they would do a call and discuss more along with Tom. Also I do think Chris talking about production is a good sign because it would be needed if they are picked for the RECOVER trial . Once again I am just a long who is over this manipulation and horrible stock price.

User Image Teleboy Posted - 8 hours ago

$AIM Pfizer names cancer specialist as new R&D head. This does not reference Ampligen but it does show the way Pfizer is thinking about future R&D with an emphasis on oncology. https://www.biopharmadive.com/news/pfizer-chris-boshoff-cso-research-development-dolsten-successor/733433/

User Image Teleboy Posted - 10 hours ago

$AIM I am re-posting this here because of continued citing of SEC rules without actually quoting them: We've been told AIM is in talks. Judging by the SEC rules that means there is no pending or proposed merger and no new equity agreement, etc. But it is reasonable to say there may be negotiations that don't have the specific goal of merger or takeover, etc. Of course it doesn't mean any or all of these things either. We don't know. Those that imply they do are not being truthful. "DEFINITION OF MATERIAL NONPUBLIC INFORMATION Information should be regarded as material if there is a reasonable likelihood that it would be considered important to an investor in making an investment decision regarding the purchase or sale of the Company’s securities...." Examples include: "News of a pending or proposed merger.... New product announcements of a significant nature.... New equity or debt offerings...." https://www.sec.gov/Archives/edgar/data/1069353/000129993308003911/exhibit2.htm

User Image skepticalbee Posted - 11 hours ago

$AIM @Maxwell_Smart The incumbent board has run AIM into the ground and repeatedly misled shareholders, all the while enriching itself in stark disproportion to what it's cost shareholders. As a result, AIM appears on the potential brink of insolvency. We can't know the Kellner Group's true aim (pun intended), but in contrast, they helm successful, well-capitalized enterprises. And they are also governed by SEC and civil law, and potentially liablevif they are deceiving shareholders while trying to get elected to the Board.

User Image Leeman02 Posted - 11 hours ago

$AIM 🤔 I wonder what Toms DCA is?

User Image skepticalbee Posted - 11 hours ago

$AIM This bears repeating for those in LaLa land, re Equels' stock purchase:

User Image GozillaPorilla Posted - 12 hours ago

$AIM added another 10k

User Image WallStreetIsNotEasy Posted - 12 hours ago

$AIM The fact that the CEO bought at the lows is a GREAT sign!! If more dilution is needed well that’s the way it has to be. We are priced at such depressed levels it’s not gonna matter much. Doesn’t change the fact that things can and 💯do change overnight in bio land. With all the phenomenal data out there , it’s only a matter of time before the true value emerges HERE I am locked 🔒 and loaded until that day 👌

User Image CEOBuysDisclosures Posted - 12 hours ago

$AIM CEO purchased 60,110 shares at $0.18 for a total of $11,000. Equels Thomas K now owns 1,552,968 shares. https://ceo-buys.com

User Image TonyClifton13 Posted - 12 hours ago

$AIM Does the insider purchase mean that a deal is not being negotiated at this moment? Does anyone know the rules of insider trading before a buyout/deal? Or is the amount spent too low to be considered ‘impactful’ in regard of insider trading? If there is no deal soon, we’re getting diluted big time after election. But that goes for both Equels and Kellner. There’s no other way to survive.

User Image gianpinco Posted - 13 hours ago

$AIM of course your avg is $6 like me

User Image Maxwell_Smart Posted - 13 hours ago

$AIM Are both choices monstrous?

User Image skepticalbee Posted - 13 hours ago

$AIM Echo this. Everyone long on this stock (which is almost everyone who tangles with it; short interest is small and is not the threat) depends on the owners of this company--all of you--to throw Equels and his ship of fools overboard before AIM runs aground and can never be righted. It's now or never.

User Image uuddlrlr Posted - 13 hours ago

$AIM CEO spent $11,000 on shares. Not impressed in the slightest. Where are the open market purchases by other board members? Where are the confidence boosting purchases of $50-100k worth of shares by senior leadership?

User Image ultimatebastos Posted - 14 hours ago

$AIM only 60 k and the croocks lose control...

User Image micklemas Posted - 14 hours ago

$AIM On November 20, 2024, Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (ticker: AIM), filed a Form 4 with the SEC, reporting the purchase of 60,110 shares of AIM common stock at $0.183 per share. Following this transaction, Mr. Equels directly owns a total of 1,552,968 shares of the company’s common stock.

User Image Zman08765 Posted - 14 hours ago

$AIM Equels buys 60,000.

User Image lktrader Posted - 14 hours ago

$AIM 60K Equels purchase?

User Image TheLionofwallstreet Posted - 14 hours ago

$AIM the biggest fuq you Tom could give these crooks is the company has been sold. You get nothing.

User Image ultimatebastos Posted - 14 hours ago

$AIM let's hope this year the Kellner virus has it's last outbreak.

User Image jonjonson1234 Posted - 15 hours ago

$AIM The production of new Alferon N Injection Active Pharmaceutical Ingredient, or API, is currently on hold. We do not know when, if ever, our products will be generally available for commercial sale for any indication

User Image Special_Ka Posted - 15 hours ago

$AIM For all the actual investors out there (there are some, I know) that hold shares of this company. I hope you will read this SEC filing. It is by the Kellner team, however the write up does outline the actions taken by the current leadership. It outlines some of the financial decisions of the current board (which I believe to be a potential explanation of yesterdays sell off, a little bit of time will tell this story). I am tired of losing money on this stupid stock... For the eligible voters, please read this prior to voting https://archive.fast-edgar.com/20241119/AN2VS62EZZ2ROZZ222TJ2ZYKKVAEZZ22D262/

User Image ultimatebastos Posted - 16 hours ago

$AIM why do the idiots quit? You just can't trust croocks no more.

User Image Slide3 Posted - 16 hours ago

$AIM For those concerned about the board wasting money, they also have an ad on X touting the Board and bad mouthing the dissidents.

User Image Jeffzhamgg Posted - 16 hours ago

$AIM another day in paradise watching naked shorts keep shorting. New supports all the way to .08 on the chart now.

User Image Paristommy Posted - 17 hours ago

$AIM Looks like the manipulation is starting early, Tom has until December 10 th to find an answer to why we have been getting manipulated for years , or find a buyer !! If not he will not get my vote!!!

Analyst Ratings
Ascendiant Capital Buy Sep 3, 24
Maxim Group Buy Oct 10, 19
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Equels Thomas K CEO & President CEO & President Nov 27 Buy 0.443 33,861 15,000 640,697 11/27/23
Equels Thomas K CEO & President CEO & President Sep 29 Buy 0.441 22,676 10,000 606,836 09/29/23
Equels Thomas K CEO & President CEO & President Aug 25 Buy 0.669 8,222 5,501 584,160 08/25/23
Equels Thomas K CEO & President CEO & President Aug 24 Buy 0.667 14,993 10,000 575,938 08/24/23
Equels Thomas K CEO & President CEO & President Jul 17 Buy 0.59 16,950 10,000 560,945 07/17/23
APPELROUTH STEWART Director Director Jan 03 Buy 0.31 80,646 25,000 217,063 01/04/23
Rodino Peter W III COO, Secretary, Gen... COO, Secretary, Gen. Counsel Jan 03 Buy 0.31 80,646 25,000 143,839 01/04/23
Equels Thomas K CEO & President CEO & President Jan 03 Buy 0.31 161,291 50,000 543,995 01/04/23